JF Medicine-B (02595.HK) plans to repurchase H shares worth no more than 350 million Hong Kong dollars.

The Smart Finance APP reported that KingMed Diagnostics Group-B (02595.HK) issued an announcement that on June 29, 2026, the board of directors formally resolved to exercise the authorization to repurchase shares, intending to repurchase H shares in the open market at a maximum amount not exceeding HK$350 million. The share repurchase period will expire at the end of the authorization period. The company will conduct share repurchases in compliance with the Listing Rules of The Stock Exchange of Hong Kong Limited.